Merck & Co. 8K Merck Announces Fourth-Quarter and Full-Year 2009 Financial Results | MRK 16 Feb 10

Exhibit 99.2

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES - SUPPLEMENTAL COMBINED NON-GAAP

FOURTH QUARTER AND FULL YEAR 2009

(AMOUNTS IN MILLIONS)

Table 4a

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect a full quarter and full year of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

For a reconciliation of GAAP sales to Supplemental Combined Non-GAAP sales see Table 4.


	“3 + 3”						“12 + 12”
	Supplemental Combined Non-GAAP						Supplemental Combined Non-GAAP
	Global 4Q		U.S. 4Q		International 4Q		Global Full Year		U.S. Full Year		International Full Year

TOTAL SALES⁽¹⁾	$	12,216	$	5,535	$	6,681	$	45,964	$	21,269	$	24,695

HUMAN HEALTH⁽²⁾		10,805		4,740		6,064		40,098		17,766		22,332

Bone, Resp., Imm., & Dermatology
Singulair		1,260		810		450		4,660		3,044		1,615
Remicade		635				635		2,327				2,327
Nasonex		286		157		129		1,179		648		530
Fosamax		285		39		246		1,100		161		939
Clarinex		155		55		100		719		249		470
Propecia		123		38		84		440		148		293
Arcoxia		98				98		358				358
Asmanex		58		55		2		214		204		10

Cardiovascular
Zetia		614		343		271		2,244		1,296		948
Vytorin		577		319		258		2,112		1,219		893
Integrilin		72		67		5		295		275		19

Diabetes & Obesity
Januvia		558		390		168		1,922		1,404		518
Janumet		202		136		66		658		472		187

Infectious Disease
PegIntron		216		23		193		844		110		735
Isentress		234		113		121		752		370		382
Primaxin		196		41		155		689		136		553
Cancidas		175		19		156		617		73		543
Avelox		118		115		4		368		353		15
Invanz		88		43		45		293		152		141
Rebetol		57				57		254		1		253
Crixivan / Stocrin		52		2		50		206		10		196

Mature Brands
Cozaar / Hyzaar		955		363		592		3,561		1,321		2,240
Zocor		139		10		129		558		45		513
Claritin Rx		109				109		433				433
Vasotec / Vaseretic		85				85		311				311
Proscar		72		2		71		291		6		285
Proventil		56		54		2		225		220		5

Neurosciences & Ophthalmology
Maxalt		156		107		49		575		398		176
Cosopt / Trusopt		134		7		127		503		39		464
Remeron		60		3		57		234		10		224
Subutex / Suboxone		56				56		211				211

Oncology
Temodar		292		103		189		1,073		387		686
Emend		88		55		33		313		198		115
Caelyx		70				70		265				265
Intron A		54		29		25		231		121		110

Vaccines
ProQuad, M-M-R II and Varivax		333		310		22		1,369		1,288		81
Gardasil		277		218		59		1,118		802		317
RotaTeq		135		123		12		522		468		54
Pneumovax		128		74		54		346		245		101
Zostavax		76		76				277		277
Women’s Health & Endocrine
Follistim / Puregon		149		45		105		546		179		368
Nuvaring		135		80		55		511		313		198

Other Human Health⁽³⁾		1,186		318		869		4,376		1,123		3,253

ANIMAL HEALTH		759		161		598		2,716		599		2,117

CONSUMER HEALTH⁽²⁾		232		214		19		1,281		1,175		105
Claritin OTC		63		62		1		406		390		16

Other Revenues⁽⁴⁾		420		420				1,870		1,729		141

⁽¹⁾	Individual products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of >$200M are shown. Sales reflect the then current foreign exchange rates.

⁽²⁾	Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Health includes US and Canada consumer product sales.

⁽³⁾	Includes Human Health products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of <$200M.

⁽⁴⁾	Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The Company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company’s product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors’ understanding of the company’s sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES - GAAP TO SUPPLEMENTAL COMBINED NON-GAAP RECONCILIATION FIRST QUARTER - THIRD QUARTER 2009

(AMOUNTS IN MILLIONS)

Table 4b

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect full quarters of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.


					“3 + 3”						“3 + 3”						“3 + 3”
	GAAP 1Q09		Adjustment 1Q09		Supp. Comb. Non-GAAP 1Q09		GAAP 2Q09		Adjustment 2Q09		Supp. Comb. Non-GAAP 2Q09		GAAP 3Q09		Adjustment 3Q09		Supp. Comb. Non-GAAP 3Q09

TOTAL SALES⁽¹⁾	$	5,385	$	5,298	$	10,683	$	5,900	$	5,634	$	11,534	$	6,050	$	5,481	$	11,531


HUMAN HEALTH ⁽²⁾		5,019		4,215		9,235		5,470		4,488		9,956		5,676		4,425		10,101

Bone, Resp., Imm., & Dermatology
Singulair		1,057				1,057		1,257				1,257		1,085				1,085
Remicade				518		518				565		565				608		608
Nasonex				306		306				321		321				266		266
Fosamax		261				261		277				277		276				276
Clarinex				174		174				226		226				164		164
Propecia		103				103		106				106		109				109
Arcoxia		81				81		88				88		90				90
Asmanex				49		49				54		54				53		53

Cardiovascular
Zetia		1		509		510		1		555		556		1		562		563
Vytorin		16		462		477		21		511		532		20		505		525
Integrilin				76		76				73		73				74		74

Diabetes & Obesity
Januvia		411				411		462				462		491				491
Janumet		128				128		155				155		173				173

Infectious Disease
PegIntron				216		216				215		215				198		198
Isentress		148				148		172				172		197				197
Primaxin		165				165		160				160		168				168
Cancidas		139				139		149				149		155				155
Avelox				109		109				71		71				70		70
Invanz		62				62		71				71		73				73
Rebetol				66		66				67		67				64		64
Crixivan / Stocrin		49				49		56				56		49				49

Mature Brands
Cozaar / Hyzaar		839				839		906				906		861				861
Zocor		137				137		141				141		141				141
Claritin Rx				132		132				96		96				95		95
Vasotec / Vaseretic		77				77		76				76		73				73
Proscar		72				72		79				79		67				67
Proventil				54		54				56		56				59		59

Neurosciences & Ophthalmology
Maxalt		133				133		141				141		144				144
Cosopt / Trusopt		121				121		125				125		123				123
Remeron				50		50				50		50				74		74
Subutex / Suboxone				50		50				52		52				53		53

Oncology
Temodar				247		247				256		256				278		278
Emend		68				68		76				76		81				81
Caelyx				61		61				68		68				67		67
Intron A				54		54				67		67				56		56

Vaccines
ProQuad, M-M-R II and Varivax		252				252		322				322		462				462
Gardasil		262				262		268				268		311				311
RotaTeq		134				134		126				126		127				127
Pneumovax		41				41		47				47		130				130
Zostavax		75				75		42				42		84				84

Women’s Health & Endocrine
Follistim / Puregon				131		131				145		145				122		122
Nuvaring				115		115				129		129				131		131

Other Human Health ⁽³⁾		185		838		1,023		146		909		1,056		183		928		1,111

ANIMAL HEALTH				621		621				672		672				664		664

CONSUMER HEALTH ⁽²⁾				384		384				381		381				283		283
Claritin OTC				149		149				108		108				85		85

Other Revenues ⁽⁴⁾		366		77		443		430		94		524		374		109		483

⁽¹⁾	Individual products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of >$200M are shown. Sales reflect the then current foreign exchange rates.

⁽²⁾	Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Health includes US and Canada consumer product sales.

⁽³⁾	Includes Human Health products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of <$200M.

⁽⁴⁾	Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES - SUPPLEMENTAL COMBINED NON-GAAP

FULL YEAR 2009

(AMOUNTS IN MILLIONS)

Table 4c

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect full quarters and a full year of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

For a reconciliation of GAAP sales to Supplemental Combined Non-GAAP sales see Tables 4 and 4b.


									“12 + 12”
	2009 - Supplemental Combined Non-GAAP
	1Q		2Q		3Q		4Q		Full Year
TOTAL SALES⁽¹⁾	$	10,683	$	11,534	$	11,531	$	12,216	$	45,964


HUMAN HEALTH⁽²⁾		9,235		9,956		10,101		10,805		40,098

Bone, Resp., Imm., & Dermatology
Singulair		1,057		1,257		1,085		1,260		4,660
Remicade		518		565		608		635		2,327
Nasonex		306		321		266		286		1,179
Fosamax		261		277		276		285		1,100
Clarinex		174		226		164		155		719
Propecia		103		106		109		123		440
Arcoxia		81		88		90		98		358
Asmanex		49		54		53		58		214

Cardiovascular
Zetia		510		556		563		614		2,244
Vytorin		477		532		525		577		2,112
Integrilin		76		73		74		72		295

Diabetes & Obesity
Januvia		411		462		491		558		1,922
Janumet		128		155		173		202		658

Infectious Disease
PegIntron		216		215		198		216		844
Isentress		148		172		197		234		752
Primaxin		165		160		168		196		689
Cancidas		139		149		155		175		617
Avelox		109		71		70		118		368
Invanz		62		71		73		88		293
Rebetol		66		67		64		57		254
Crixivan / Stocrin		49		56		49		52		206

Mature Brands
Cozaar / Hyzaar		839		906		861		955		3,561
Zocor		137		141		141		139		558
Claritin Rx		132		96		95		109		433
Vasotec / Vaseretic		77		76		73		85		311
Proscar		72		79		67		72		291
Proventil		54		56		59		56		225

Neurosciences & Ophthalmology
Maxalt		133		141		144		156		575
Cosopt / Trusopt		121		125		123		134		503
Remeron		50		50		74		60		234
Subutex / Suboxone		50		52		53		56		211

Oncology
Temodar		247		256		278		292		1,073
Emend		68		76		81		88		313
Caelyx		61		68		67		70		265
Intron A		54		67		56		54		231

Vaccines
ProQuad, M-M-R II and Varivax		252		322		462		333		1,369
Gardasil		262		268		311		277		1,118
RotaTeq		134		126		127		135		522
Pneumovax		41		47		130		128		346
Zostavax		75		42		84		76		277

Women’s Health & Endocrine
Follistim / Puregon		131		145		122		149		546
Nuvaring		115		129		131		135		511

Other Human Health⁽³⁾		1,023		1,056		1,111		1,186		4,376

ANIMAL HEALTH		621		672		664		759		2,716

CONSUMER HEALTH⁽²⁾		384		381		283		232		1,281
Claritin OTC		149		108		85		63		406

Other Revenues⁽⁴⁾		443		524		483		420		1,870

⁽¹⁾	Individual products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of >$200M are shown. Sales reflect the then current foreign exchange rates.

⁽²⁾	Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Health includes US and Canada consumer product sales.

⁽³⁾	Includes Human Health products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of <$200M.

⁽⁴⁾	Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

MERCK & CO., INC.

EQUITY INCOME / JV SALES / OTHER (INCOME) EXPENSE - GAAP

FOURTH QUARTER

2009

Table 6

EQUITY INCOME FROM AFFILIATES (millions of dollars)

4Q09

4Q08

FY 2009

FY 2008

MERCK / SCHERING-PLOUGH⁽¹⁾

151.0

378.1

1,195.5

1,536.3

ASTRAZENECA LP

191.7

266.8

674.3

598.4

Other⁽²⁾

31.1

75.1

365.2

425.9

TOTAL

373.8

720.0

2,235.0

2,560.6

⁽¹⁾	Reflects equity income from the Merck/Schering-Plough partnership until the merger with Schering-Plough at which time the joint venture became wholly-owned by the Company.

⁽²⁾	Primarily reflects results for Merial Limited (until disposition on September 17, 2009), Sanofi Pasteur MSD and Johnson & JohnsonºMerck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.

Merial⁽¹⁾

4Q09

4Q08

Period from
Jan. 1, 2009
until
Sept. 17, 2009

FY 2008

FRONTLINE, other fipronil

—

152.0

783.9

1,053.0

BIOLOGICALS

—

208.8

524.5

789.7

IVOMEC, HEARTGARD, other avermectins

—

96.8

341.4

511.8

Other Animal Health

—

67.4

199.7

288.2

TOTAL MERIAL SALES

—

525.0

1,849.5

2,642.7

⁽¹⁾	On September 17, 2009, Merck sold its ownership interest in Merial Limited. Sales figures for 2009 are reported until the date of disposition.

Sanofi Pasteur MSD

4Q09

4Q08

FY 2009

FY 2008

GARDASIL

132.1

171.2

549.2

865.3

FLU VACCINES

82.3

112.7

249.4

229.9

OTHER VIRAL VACCINES

33.2

24.4

112.1

105.1

HEPATITIS VACCINES

9.5

15.9

44.2

72.6

ROTATEQ

12.7

7.2

42.2

28.4

Other Vaccines

166.5

145.2

591.5

583.5

TOTAL SANOFI PASTEUR MSD SALES

436.3

476.6

1,588.6

1,884.8

OTHER (INCOME) EXPENSE, NET (millions of dollars)

4Q09

4Q08

FY 2009

FY 2008

INTEREST INCOME

(10.5

)

(147.2

)

(210.2

)

(631.4

)

INTEREST EXPENSE

167.0

56.7

458.0

251.3

EXCHANGE (GAINS) LOSSES

(9.4

)

73.8

(12.4

)

147.4

Other, net⁽¹⁾

(7,961.9

)

(10.1

)

(10,904.9

)

(2,085.4

)

TOTAL

(7,814.8

)

(26.8

)

(10,669.5

)

(2,318.1

)

⁽¹⁾	Other, net in 2009 primarily reflects a $7.5 billion gain associated with the Merck/Schering-Plough partnership and a $3.2 billion gain on the sale of Merck’s ownership interest in Merial Limited. Other, net in 2008 primarily reflects a $2.2 billion gain on distribution from AstraZeneca LP.

Merck & Co. (MRK) 8-KMerck Announces Fourth-Quarter and Full-Year 2009 Financial Results